18F-FDG-PET/CT

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 2, 2012, Pages 138-150

  Chierichetti, F ^a   Pizzolato, G ^b  

^a General Hospital   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Clinical protocols; Necrosis; Neoplasm grading; Positron emission tomography; Prognosis; Tomography, X ray computed

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ACETIC ACID C 11; AMINO ACID DERIVATIVE; ANGIOGENESIS INHIBITOR; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; METHIONINE C 11; METHOTREXATE; TEMOZOLOMIDE; TRACER; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

BRAIN FUNCTION; BRAIN LYMPHOMA; BRAIN METASTASIS; BRAIN TUMOR; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FALSE NEGATIVE RESULT; GAMMA KNIFE RADIOSURGERY; GLIOBLASTOMA; GRAY MATTER; HEAD AND NECK CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDICAL DECISION MAKING; MEDICAL DEVICE; MENINGIOMA; MONITORING; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR NECROSIS; WHITE MATTER; BRAIN; COMPUTER ASSISTED TOMOGRAPHY; IMAGE SUBTRACTION; METHODOLOGY; PATHOLOGY; RADIOGRAPHY;

BRAIN; BRAIN NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84864386153     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Kläsner BD, Krause BJ, Beer AJ, Drzezga A. PET imaging of gliomas using novel tracers: a sleeping beauty waiting to be kissed. Expert Rev. Anticancer Ther 2010;10:609-13.
2. Gallagher BM, Ansari A, Atkins H, Casella V, Christman DR, Fowler JS et al. Radiopharmaceuticals XXXVII. 18F-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animal. J Nucl Med 1977;18:990-6.
3. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T et al. The [18F] fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979;44:127-37. (Pubitemid 9089586)
4. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD et al. The (14C) deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916. (Pubitemid 8098854)
5. Huang SC, Phelps ME, Hoffmann EJ, Sideris K, Selin CJ, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. American Journal of Physiology 1980;232:E69-E82.
6. Reivich M, Alavi A, Wolf SA, Fowler J, Russel J, Arnett C et al. Glucose metabolic rate kinetic model parameter determination in humans: the Lumped constants and rate constants for (18F) fluorodeoxyglucose and (HC) deoxyglucose. J Cereb Blood Flow Metabolism 1985;5:179-92. (Pubitemid 15123203)
7. Dienel GA, Cruz NF, Sokoloff L. metabolites of 2-deoxy-(14C) glucose in plasma and brain: influence on rate of glucose utilization determined with glucose method in rat brain. J Cereb Blood Flow Metabolism 1993;13:315-37.
8. Pelligrino DA, LaManna JC, Duchrow RB, Bryan RM, Harik SI. Hyperglycemia and blood-brain barrier glucose transport. J Cereb Blood Flow Metabolism 1992;12:887-99.
9. Ishizu k, Nishizawa S, Yonekura Y, Sadato N, Magata Y, Tamaki N et al. Effects of hyperglycaemia on FDG uptake in human brain and glioma. J Nucl Med 1994;35:1104-9.
10. Rosenfeld SS, Hoffmann JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. Studies of primary central nervous system lymphoma with fluorine-18- fluorodeoxyglucose positron emission tomography. J Nucl Med 1992;33:532-5.
11. Roelcke U, Blasberg RG, von Amnion K, Hofer S, Vontobel P, Maguire RP et al. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 1998;39:878-84.
12. Prieto E, Marti-Climent JM, Dominiguez-Prado I, Garrastachu P, Diez-Valle R, Teiada S et al. Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation. J Nucl Med 2011;52:865-72.
13. Horky LL, Hsiao EM, Weiss SE, Drappatz J, Gerbaudo VH. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence. J Neurooncol 2011;103:137-46.
14. Wrenn FR Jr, Good ML, Handler P. The use of positron-emitting radioisotopes for the localization of brain tumors. Science 1951;113:525-7.
15. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8:519-30.
16. Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET and immunoistochemical studies. J Nucl Med 2006;47:410-8. (Pubitemid 46768482)
17. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH et al. Glucose utilization of cerebral gliomas measured by (18F) fluoredoxyglucose and positron emission tomography. Neurology 1982;32:1323-9. (Pubitemid 13218489)
18. DiChiro G., Brooks R. A PET quantitation: blessing and curse. J Nucl Med 1988;29:1603-4.
19. Patronas NJ, Di Chiro G, Kufta CV, Bairamian D, Kornblith PL, Simon R et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816-22. (Pubitemid 15009404)
20. Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47-52.
21. Tyler JL, Diksic M, Villemure JG, Evans AC, Meyer E, Yamamoto YL et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987;28:1123-33. (Pubitemid 17146831)
22. Di Chiro G, Brooks RA. PET-FDG of untreated and treated gliomas. J Nucl Med 1988;29:421-3.
23. Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rosotmilly R et al. Volumetric analysis of 18F-FDG PET in gliobalstoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 2002;43:1667-73. (Pubitemid 35424993)
24. Di Chiro G. Positron emission tomography using (18F) fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1986;22:360-71. (Pubitemid 17074568)
25. Hoffmann JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567-75. (Pubitemid 23115656)
26. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45. (Pubitemid 46909922)
27. DeLaPaz RL, Patronas NJ, Brooks RA, Smith BH, Kornblith PL, Milam H et al. Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors. Am J Neuroradiol 1983;4:826-9.
28. Duffau H. Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity. Lancet Neurol 2005;4:476-86. (Pubitemid 40982458)
29. Camargo EE, Szabo Z, Links JM, Sostre S, Dannals RF, Wagner HN Jr. The influence of biological and technical factors on the variability of global and regional brain metabolism of 2-(18F) fluoro2-deoxy-D-glucose. J Cer Blood Flow Metabolism 1992;12:281-90.
30. Golan H, Kennedy JA, Frenkel A, Parmet Y, Feintuch A, Levi O et al. Brain mapping of patients with lung cancer and controls: inquiry into tumor-to-brain communication. J Nucl Med 2009;50:1072-5.
31. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studied of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80. (Pubitemid 20195640)
32. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
33. Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY et al. Application of novel response/progression measures for surgically delivered therapies for gliomas. Neurosurgery 2011 [Epub ahead of print].
34. Van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L et al. Response assessment in neuro-oncology (a report of the Rano group): assessment of outcome in triasl of diffuse low-grade gliomas. Lancet Oncol 2011;12:583-93.
35. Patronas NJ, Di Chiro G, Brooks RA, DeLaPaz RL, Kornblith PL, Smith BH et al. Work in progress: (18F) fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982;144:886:9.
36. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathology studies. AJR 1988;150:189-97. (Pubitemid 18027033)
37. Doyle WK, Budinger TF, Valk PE, Levin VA, Gutin PH. Differentiation of cerebral radiation necrosis from tumor recurrence by (18F)FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 1987;11:563-70. (Pubitemid 17104751)
38. Goldman S, Levivier M, Pirotte B, Brucher JM, Wilder D, Dambaut P et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997;38:1459-62. (Pubitemid 27386211)
39. Galban CJ, Bhojani MS, Lee KC, Meyer CR, Van Dort M, Kuszpitl K et al. Evaluation of treatment associated inflammatory response on diffusion weighted-MRI and FDG-PET imaging biomarkers. Clin Cancer Res 2010;16:1542-52.
40. Maruyama I, Sadato N, Waki A, Tsuchida T, Yoshida M, Fujibayashi Y et al. Yperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: a PET study. J Nucl Med 1999;40:1085-90. (Pubitemid 29315495)
41. Yamamoto T, Nishizawa S, Maruyama I, Yoshida M, Tsuchida T, Waki A et al. Acute effects of stereotactic radiosurgery on the kinetics of glucose metabolism in metastatic brain tumors: FDG PET study. Ann Nucl Med 2001;15:103-9. (Pubitemid 32521919)
42. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK: Use of [18F] fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol. 1993;33:540-8. (Pubitemid 23143040)
43. Valk PE, Budinger TF, Levin VA, Silver P, Gulin PH, Doyle WK. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 1988;69:830-8.
44. Holodny AI, Makeyev S, Beattie BJ, Riad S, Blasberg RG. Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose- positron-emission tomography and gadolinium-enhanced MR imaging. AJR 2010;31:1042-8.
45. Di Chiro G, Hatazawa I, Katz DA, Rizzoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 1987;164:521-6. (Pubitemid 17097978)
46. Barker FG 2nd, Chang SM, Valk PE, Pounds TR, Prados MD. 18-fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115-26. (Pubitemid 26425516)
47. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Saffer M et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:37.
48. Praf R, Galeano I, Lucas A, Martinez JC, Martin M, Amador R et al. Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion and 2-(18F) fluoro-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas. J Clin Neurosci 2010;17:50-3.
49. Blasberg RG. Prediction of brain tumor therapy response by PET. J Neurooncol 1994;22:281-6.
50. Lucignani G. PET imaging with hypoxia tracers: a must in radiation therapy. Eur J Nucl Med Mol Imaging 2008;35:838-42.
51. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-32.
52. MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009;91:85-94.
53. Wang D, Schultz CJ, Jursinic PA, Bialkowski M, Zhu XR, Brown WD et al. Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2006;65:143-51.
54. Lee JK, Liu RS, Shiang HR, Pan DH. Usefulness of semiquantitative FDG-PET in the prediction of brain tumor treatment response to gamma knife radiosurgery. J Comput Assist Tomogr 2003;27:525-9. (Pubitemid 36935908)
55. Levivier M, Wikler D, Goldman S, Pirotte B, Brotchi J. Positron emission tomography in stereotactic conditions as a functional imaging technique for neurosurgical guidance. In: Alexander EB III, Maciunas RM, eds. Advanced Neurosurgical Navigation. New York, NY: Thieme Medical Publishers, Inc.; 1999. p. 85-99.
56. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997;38:1459-62. (Pubitemid 27386211)
57. Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004;45:1146-54. (Pubitemid 47611659)
58. Douglas JG, Stelzer KJ, Mankoff DA, Tralins KS, Krohn KA, Muzi M et al. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2006;64:886-91. (Pubitemid 43183589)
59. Liu RS, Chang CP, Guo WY, Pan DHC, Ho DMT, Chang CW et al. 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of γ-knife radiosurgery. J Nucl Med 2010;51:883-91.
60. Brandes AA, Rigon A, Zampieri P, Ermani M, Carollo C, Altavilla G et al. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme. A Phase II study. Cancer 1998;82:355-61. (Pubitemid 28060254)
61. Chamley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:331-8. (Pubitemid 44332726)
62. Pardo FS, Aronen HJ, Fitzek M, Kennedy DN, Efird J, Rosen BR et al. Correlation of FDG-PET interpretation with survival in a cohort of glioma patients. Anticancer Res 2004;24:2359-65. (Pubitemid 39166318)
63. Rosenschöld PM, Engelholm S, Ohlhues L, Law I, Vogelius I, Engelholm SA. Photon and proton therapy planning comparison for malignant glioma based on CT, FDG-PET, DTI-MRI and fiber tracking. Acta Oncol 2011;50:777-83.
64. Sandu N, Schaller B. Stem cell transplantation in brain tumors: a new field for molecular imaging? Mol Med 2010;16:433-7.
65. Lindsay MJ, Siegel BA, Tunis SR, Hillner BE, Shields AF, Carey BP et al. The National Oncologic PET Registry: expanded Medicare coverage for PET under coverage with evidence development. AJR 2007;188:1109-13. (Pubitemid 46496951)
66. Hillner BE, Siegel BA, Shields AF, Duan F, Gareen IF, Hanna L et al. Impact of dedicated brain PET on intended patient management in participants of the National Oncologic PET Registry. Mol Imaging Biol 2011;13:161-5.
67. Pietrzyk U, Herholz K, Fink G, Jacobs A, Mielke R, Slansky I et al. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 1994;35:2011-8. (Pubitemid 24376621)
68. Townsend DD. Dual-modality imaging: combining anatomy and function. J Nucl Med 2008;49:938-55.
69. Krüger S, Mottaghy FM, Buck AK, Maschke S, Kley H, Frechen D et al. Brain metastasis in lung cancer. Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the initial staging. Nuklearmedizin 2011;50:101-6.
70. Palomar Muñoz A, García Vicente AM, Bellón Guardia ME, González García B, Talavera Rubio MP, Pilkington Woll JP et al. Is a selective brain (18)F-FDG PET/CT study profitable in patients with small cell lung cancer? Rev Esp Med Nucl 2011 [Epub ahead of print].
71. van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol 2010;20:1456-67.
72. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S-150S.